Ligand-Gated Ion Channel Database

Structural and Functional Insights into Surfactant Protein A: Advances in Antibody-Based Research

• Nicolas
• August 26, 2025
• 0

1) SP-A at a glance (collectin biology, genes, and localization)

Surfactant Protein A (SP-A) is a collagen-containing C-type lectin (collectin) secreted into the alveolar hypophase by type II pneumocytes, where it contributes to surfactant homeostasis and host defense. Core background on pulmonary surfactant and alveolar cell biology: StatPearls—Surfactant, StatPearls—Alveolar Cells, StatPearls—Anatomy, Thorax, Lungs, and a surfactant overview in Han et al. (NIH/PMC). The human locus encodes SFTPA1 and SFTPA2; gene pages and recent updates: NCBI Gene—SFTPA1. Recent reviews summarize genetic/epigenetic variation and functional divergence of SP-A1 vs SP-A2: Floros et al. 2021 (PubMed), Silveyra et al. 2013 (PubMed). CNIB+2CNIB+2PMCPubMed

2) Oligomeric architecture and domains

SP-A is built from trimeric subunits (each monomer has an N-terminal cysteine-rich segment, a collagen-like region, an α-helical “neck,” and a C-terminal carbohydrate-recognition domain, CRD). Six trimers assemble into a characteristic octadecamer, often described as a “flower bouquet” architecture. Educational and primary-source depictions include: Hawai‘i (edu) review PDF—Figure on SP-A octadecamer, Ohio State (edu) thesis—SP-A octadecamer schematic, Penn State (edu) hosted review PDF. High-resolution structures are available for the neck+CRD trimer: Head et al., 2003 (PubMed) and ligand complexes: Shang et al., 2011 (PubMed) / NIH/PMC entry. General collectin architecture overview: Watson et al., 2018 (NIH/PMC). Université d’Hawaïresearch.cbc.osu.eduCiteSeerXPubMed+1PMC+1

Implications for antibodies: The multimeric bouquet increases avidity for repetitive glycans; antibodies targeting CRD vs collagen/neck epitopes will report distinct conformational states and multimer content in biochemical/EM assays.

3) Pattern recognition and macrophage signaling

SP-A binds carbohydrate motifs on pathogens and altered self via its CRD and modulates alveolar macrophage programs. Documented receptors and signaling axes include:

• SP-R210 (MYO18A): A macrophage receptor implicated in phagocytic uptake and cytokine tuning (Penn State—pure.psu.edu; confirmatory immunoprecipitation in NIH/PMC).

• Calreticulin/CD91 complex and SIRPα pathways drive dual pro- and anti-inflammatory outputs depending on binding orientation (PubMed: 12244199, PubMed: 14531999, NIH/PMC review).

• TLR2/TLR4 modulation: SP-A increases TLR2 expression but dampens TLR2/TLR4 signaling in human macrophages (NIH/PMC).

These mechanisms underpin opsonophagocytosis, chemotaxis, and resolution of inflammation in the distal lung. Penn StatePMC+2PMC+2PubMed+1

4) Pathogen interaction case studies

Influenza A virus (IAV). SP-A binds IAV and attenuates infectivity; early studies showed sialic-acid–dependent interactions and HA inhibition (PubMed: 7844369; NIH/PMC). In macrophages, SP-A delays IAV endosomal trafficking and infection (PubMed: 36960051; NIH/PMC). SP-A deficiency exaggerates early inflammatory responses to IAV in mice (PubMed: 11867335). PubMed+2PubMed+2PMC+1

Mycobacterium tuberculosis (Mtb). SP-A promotes attachment and enhances macrophage phagocytosis of Mtb (NIH/PMC, Downing et al.; PubMed: 7594549). Related collectin SP-D exhibits complementary, sometimes opposing, effects via ManLAM binding (PubMed: 10384130; NIH/PMC). Mechanistic reviews: NIH/PMC—SP-A suppresses reactive nitrogen species in Mtb, and Mtb lipoglycan recognition. PMC+3PMC+3PMC+3PubMed+1

Clinical genetics context. Variants in SFTPA1/SFTPA2 have been linked to interstitial lung disease phenotypes and susceptibility traits (NIH/PMC 2022 review; CF/airways genetics associations: PubMed: 16429424). PMCPubMed

5) How antibodies enable SP-A research

5.1 Monoclonal vs polyclonal SP-A antibodies (specificity and use-cases)

• Monoclonal antibodies (mAbs) provide epitope-level specificity—useful to distinguish CRD vs collagen/neck epitopes, detect oligomer-dependent conformers, or separate SP-A1 vs SP-A2 variant-specific motifs when available.

• Polyclonal antibodies (pAbs) maximize sensitivity across isoforms and post-translational variants, aiding capture from BAL fluid and tissue sections.

Technical primers: NCBI Bookshelf—Monoclonal Antibody Production, “Understanding How Monoclonal Antibodies Work”, and immunology toolboxes for IP/Co-IP (NCBI Immunobiology Appendix). Comparative sensitivity in diagnostic pathology: an example survey including SP-A mAbs in lung tumors (NIH/PMC). CNIB+2CNIB+2PMC

5.2 Structural biology with antibodies (crystallography and cryo-EM)

• Crystallography: SP-A structural snapshots include the trimeric neck+CRD and ligand-bound complexes that map metal and sugar binding sites (PubMed: 12913002; NIH/PMC complex structures).

• Cryo-EM aided by Fabs: Although most high-resolution SP-A datasets are X-ray–based, antibody fragments (Fabs) are widely used to increase apparent size, enforce orientation, and stabilize flexible proteins in single-particle cryo-EM—general methods and case studies: Wu et al., 2012 (NIH/PMC), Kung et al., 2024 (NIH/PMC), Mishra et al., 2023 (PubMed), Lyumkis et al., 2013 (NIH/PMC). These strategies are directly transferable to SP-A CRD/neck trimers and to full supratrimers if sample heterogeneity is controlled. PubMed+1PMC+3PMC+3PMC+3

5.3 Immunoprecipitation (IP/Co-IP) and interactome mapping

SP-A–interacting proteins can be captured either with anti-SP-A antibodies or reciprocal IP using receptor-specific antibodies. Examples include assignments around MYO18A (SP-R210) and immune receptors in human cells (NIH/PMC). Protocol resources for IP/ChIP: Bookshelf—ChIP in budding yeast, X-ChIP workflow, and methodology figures (EDEM Co-IP example) Bookshelf figure. In epithelial signaling contexts, co-IP combined with ligand blots has been used to probe SP-A interactions with EGFR pathways in A549 cells (NIH/PMC). PMC+1CNIB+2CNIB+2

5.4 Immunohistochemistry and immunogold EM

Anti-SP-A antibodies localize SP-A to lamellar body membranes, tubular myelin, and type II cell microvilli by EM/IHC (NIH/PMC—lamellar body pathway; PubMed: CD9/SP-A EM). In lung injury models, immunogold EM shows altered SP-A distribution in tubular myelin after ischemia-reperfusion (NIH/PMC). PMC+2PMC+2

6) Experimental considerations for SP-A antibodies

• Epitope & isoform awareness. SP-A1 vs SP-A2 differences can alter epitope exposure and oligomerization; consult variant-focused analyses (NIH/PMC, NIH/PMC 2021).

• Controls for specificity. Include knockout controls where feasible—SP-A-deficient mice are well established (NIH/PMC review; early SP-A−/− phenotyping: PubMed: 9126996, PubMed: 9761768).

• Matrix effects. BAL fluid contains surfactant lipids/proteins; detergent and calcium conditions should be optimized to preserve CRD binding and supratrimer integrity during IP/ELISA. Background on surfactant biophysics and SP-A contributions to surface activity: NIH/PMC, NIH/PMC.

• Cross-reactivity. Sequence/structure homology with SP-D suggests careful validation against SP-D controls; structural and ligand-binding references for SP-D are useful benchmarks (PubMed 26953329; NIH/PMC, NIH/PMC). PMC+5PMC+5PMC+5PubMed+2PubMed+2

7) Application highlights: what SP-A antibodies enable

• Quantitative tissue mapping (IHC/EM): Detect type II cells, lamellar bodies, and extracellular tubular myelin. EM/IHC examples: lamellar body pathway and injury models (NIH/PMC, NIH/PMC).

• Mechanistic immunology (IP/flow/WB): Track receptor occupancy (e.g., SP-R210/MYO18A, calreticulin/CD91, SIRPα) and TLR signaling modulation (pure.psu.edu, PubMed 12244199, PubMed 14531999, NIH/PMC).

• Pathogen-binding assays: ELISA or glycan arrays to quantify SP-A–IAV and SP-A–Mtb interactions (PubMed 7844369; NIH/PMC).

• Variant-aware translational studies: Link SP-A haplotypes to disease phenotypes (e.g., CF modifiers, fibrosis) using genotype-stratified antibody readouts (PubMed 16429424; NIH/PMC 2022). PMC+3PMC+3PMC+3Penn StatePubMed+2PubMed+2

8) Practical notes for reproducibility

• Antibody choice. Use mAbs for epitope-defined tasks (e.g., CRD-blocking assays, epitope-specific IP); use pAbs for sensitive detection in complex matrices. General methods and pitfalls: Bookshelf—Monoclonal Antibody Production, TRP antibody lessons (Bookshelf).

• Reciprocal IP & orthogonal validation. Combine anti-SP-A IP with receptor-specific IP, then verify by MS, ligand blot, or flow cytometry; Co-IP/ChIP technique primers: Bookshelf, Bookshelf.

• Knockout and peptide competition controls. Where possible, include SP-A−/− tissue or peptide-blocked primary Abs as negative controls (NIH/PMC review of SP-A KO mice).

• Cryo-EM sample prep. Consider Fab-locking strategies (e.g., rigid Fabs or bivalent Fabs) to stabilize SP-A trimers for high-resolution reconstructions (Wu 2012; Kung 2024; Mishra 2023). CNIB+3CNIB+3CNIB+3PMC+2PMC+2PubMed

9) Selected authoritative links (.gov/.edu) to cite in-text

• Background & genes: NCBI Gene—SFTPA1, StatPearls—Surfactant, StatPearls—Alveolar Cells.

• Structure: Head et al. 2003 (PubMed), Shang et al. 2011 (PubMed), Hawai‘i edu PDF, OSU edu thesis, PSU edu PDF.

• Receptors & signaling: pure.psu.edu SP-R210, Calreticulin/CD91 (PubMed), SIRPα (PubMed), TLR modulation (NIH/PMC).

• Influenza: SP-A–IAV binding (PubMed), HA inhibition (NIH/PMC), Endosomal trafficking (PubMed).

• Mycobacterium: SP-A promotes attachment (NIH/PMC), SP-A enhances phagocytosis (PubMed).

• KO mouse controls: SP-A KO review (NIH/PMC), GBS susceptibility (PubMed), P. aeruginosa susceptibility (PubMed).

• Methods: Bookshelf—Monoclonal production, IP/Co-IP primers, ChIP protocols, X-ChIP, Fab-assisted cryo-EM (NIH/PMC), Rigid Fabs (NIH/PMC).

• Surfactant Protein A (SP-A) antibody, SP-A monoclonal antibody, SP-A polyclonal antibody, collectin CRD, alveolar macrophages, pattern-recognition receptor, calreticulin/CD91, SIRPα, SP-R210/MYO18A, TLR2/TLR4 modulation, influenza A virus, Mycobacterium tuberculosis, cryo-EM with Fab fragments, X-ray crystallography of SP-A CRD, immunoprecipitation of SP-A complexes, immunogold electron microscopy.

Conclusion

SP-A’s octadecameric collectin architecture and CRD-mediated pattern recognition underlie broad innate-immune functions in the lung. Antibodies against SP-A—selected appropriately as monoclonal vs polyclonal—are central to (i) precise localization in tissue and EM, (ii) quantitative receptor/ligand mechanistic studies via IP/Co-IP and ligand blots, and (iii) structural interrogation of SP-A subdomains (with Fab-assisted cryo-EM approaches increasingly applicable). Together, these antibody-based toolkits continue to resolve how SP-A modulates pathogen handling (IAV, Mtb) and macrophage signaling in health and disease. Université d’HawaïPubMed+2PubMed+2PMC